Clinical Trial Detail

NCT ID NCT02565992
Title Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Viralytics
Indications

melanoma

Therapies

Coxsackievirus A21 + Pembrolizumab

Age Groups: adult

No variant requirements are available.